By Stephen Nakrosis
Shares of biopharmaceutical company Cytokinetics were trading in the red in the after-hours market following news the Food and Drug Administration extended the prescription drug user fee act action date for the new drug application for aficamten.
The company is evaluating aficamten to treat patients with obstructive hypertrophic cardiomyopathy, a thickening of the heart muscle.
The FDA said it needed additional time to conduct a full review of the company's proposed risk evaluation and mitigation strategy, Cytokinetics said. No additional clinical data or studies have been requested by the FDA, the company also said.
After the bell, the company's shares were trading 13% lower, at $37.10. The stock closed Thursday's regular session at $42.92, basically flat on the day.
Year to date, the stock is down by over 33%.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 01, 2025 18:45 ET (22:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。